ABSTRACT
The COVID-19 Treatment QuickStart Consortium[1] worked with governments in 7 low- and middle-income countries, Ghana, Laos, Malawi, Nigeria, Rwanda, Uganda, and Zambia, to implement COVID-19 test-and-treat programs at 776 health facilities, including training over 5,000 staff and facilitating a donation of 11,300 courses of the oral antiviral nirmatrelvir/ritonavir for treatment. This paper describes the process of implementing COVID-19 test-and-treat programs in each country, provides aggregate program monitoring data on numbers tested and treated from program initiation through June 2024, and analyzes program enablers and challenges. Between country-level program initiation (ranging from December 2022 for Zambia to September 2023 for Uganda) and June 2024, a total of 731,970 SARS-CoV-2 tests were conducted. Of 6,724 positive tests, a subset were documented to meet eligibility criteria for nirmatrelvir/ritonavir initiation, and 3,041 patients were prescribed nirmatrelvir/ritonavir. The largest number of prescriptions was in Zambia. Program enablers included decentralization of services, task-shifting from higher to lower health worker cadres, increased access to point of care antigen tests - including self-tests, and the integration of COVID-19 with other health services. Challenges included COVID-19 de-prioritization at the time of program rollout, test commodity stockouts and expiries, and dwindling national surveillance efforts. Learnings from rapid initiation and scale-up of COVID-19 test-and-treat programs in these 7 countries can be used to inform future pandemic preparedness strategies in LMICs.
Competing Interest Statement
Christian Ramers served on the Advisory Board for Pfizer and received consulting fees he has also received consulting fees or honoraria from Gilead Sciences, Viiv, and AbbVie. All other authors declare no competing interests
Clinical Protocols
https://doi.org/10.1101/2024.10.25.24316111
Funding Statement
This work was funded by grants from Pfizer, the Open Society Foundations, and the Conrad N. Hilton Foundation. The funders played no role in study design, data collection, analysis, or interpretation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Duke University Institutional Review Board (Pro00111388), The study was also approved by the local institutional review boards in each country participating in individual-level data collection: Ghana, Malawi, Rwanda, Zambia, and Nigeria.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data available on reasonable request and approval of all relevant parties (e.g., country Ministry of Health).
